

Tuesday 19 October (times in CET)	
(times in GE1)	
13:00-13:10	Welcome WHO Director-General Tedros Adhanom Ghebreyesus, WHO, Geneva, Switzerland (pre-recorded Welcome TBC) & Maria Zambon (Chair of ISIRV), PHE, London, UK
13:10-15:55	Session 1: Pandemic Response and Surveillance Co-Chairs: Rick Bright, The Rockefeller Foundation, Washington, D.C., USA and TBC
13:10-13:50	5.6., Co. (and 150
	Keynote Talk COVID-19 Pandemic: Response and Preparing for the Future Mike Ryan or Sylvie Briand, WHO, Geneva, Switzerland (TBC)
13:50-14:15	How do respiratory viruses cause diseases? Yoshi Kawaoka, University of Wisconsin-Madison, WI, USA and University of Tokyo, Japan
14:15-14:40	Leveraging GISRS in a Pandemic Response Wenqing Zhang, WHO, Geneva, Switzerland
14:40-15:05	SARS-CoV-2 Evolution: Implications for Vaccine Strain Selection Kanta Subbarao, WHO CC for Reference and Research on Influenza, Melbourne, Australia
15:05-15:30	Monitoring Influenza Antiviral Resistance: What Lessons are There for SARS-CoV-2 Larisa Gubareva, CDC, Atlanta, GA, USA
15:30-15:55	Animal Reservoirs and Future Risks Ron Fouchier, Erasmus MC, Rotterdam, The Netherlands
15:55-16:05	Comfort Break
16:05-17:35	Session 2 (Oral Abstract Session 1) Co-Chairs: 6 x 15 min presentations (12 plus 3 for Q&A)
17:35	Close of Day 1 and Poster Viewing



Wednesday 20 October (times in CET)	
13:00-15:50	Session 3: Treatment
	Co-Chairs:
13:05-13:45	Keynote Talk Severe COVID-19, Influenza, and RSV Pathogenesis: Similarities and Differences Peter Openshaw, Imperial College, London, UK
13:45-14:10	Lessons Learned from Coronavirus Animal Models Timothy Sheahan, UNC, Chapel Hill, NC, USA
14:10-14:35	Current Status of Antiviral Therapy for COVID-19 and Influenza: WHO Perspectives Janet Diaz, WHO, Geneva, Switzerland
14:35-15:00	Immune Modulation and Biomarkers in COVID-19 John Beigel, NIH, Rockville, MD, USA
15:00-15:25	SARS-CoV-2 Variants: Implications for Monoclonals Tyler Starr, Fred Hutchinson Cancer Research Center Seattle, WA, USA
15:25-15:50	Long COVID: Interventions to Reduce Risk or Treat Charlotte Summers, University of Cambridge/Addenbrooke's Hospital, Cambridge, UK
15:50-16:00	Comfort Break
16:00-17:00	Session 4: (Oral Abstract Session 2) Co-Chairs: 4 x 15 min presentations (12 plus 3 for Q&A)
17:00	Close of Day 2 and Poster Viewing



Thursday 21 October (times in CET)	
13:00-15:00	Session 5: Prevention and Response Co-Chairs: Ann Moen, WHO, Geneva, Switzerland and TBC
13:05-13:45	Keynote Talk Novel Vaccines for COVID-19, Influenza, and RSV Barney Graham, USA
13:45-14:10	Non-pharmaceutical Interventions to Prevent RVIs Ben Cowling, University of Hong Kong, Hong Kong SAR, China
14:10-14:35	Preventing RVIs in Pregnant Women and Infants Marta Nunes, Wits Vaccines & Infectious Diseases Analytics (VIDA) Research Unit, Johannesburg, South Africa
14:35-15:00	Outbreak Risk Communication: Role of the Media Glen Nowak, University of Georgia, Athens, GA, USA
15:00-15:10	Comfort Break
15:10-16:40	Session 6: (Oral Abstract Session 3 – Late Breakers) Co-Chairs: 6 x 15 min presentations (12 plus 3 for Q&A)
16:40-17:20	Session 7: Panel Discussion Preparing for the next Event: Surveillance, Clinical Research, and Prevention Strategies Chair: Michael Jacobs Discussants: Ann Moen, Ben Cowling, Maria Zambon, Peter Horby & Soumya Swaminathan
17:20-17:30	Close of Conference